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Inflammatory breast cancer (IBC) is a rare yet aggressive form of breast cancer. We examined differences in patient demographics
and outcomes in IBC compared to locally advanced breast cancer (LABC) and all other breast cancer patients from the Breast and
Prostate Cancer Data Quality and Patterns of Care Study (POC-BP), containing information from cancer registries in seven states.
Out of 7,624 cases of invasive carcinoma, IBC and LABC accounted for 2.2% (𝑁 = 170) and 4.9% (𝑁 = 375), respectively. IBC
patients were more likely to have a higher number (𝑃 = 0.03) and severity (𝑃 = 0.01) of comorbidities than other breast cancer
patients. Among IBC patients, a higher percentage of patients with metastatic disease versus nonmetastatic disease were black,
on Medicaid, and from areas of higher poverty and more urban areas. Black and Hispanic IBC patients had worse overall and
breast cancer-specific survival than white patients; moreover, IBC patients with Medicaid, patients from urban areas, and patients
from areas of higher poverty and lower education had worse outcomes. These data highlight the effects of disparities in race and
socioeconomic status on the incidence of IBC as well as IBC outcomes. Further work is needed to reveal the causes behind these
disparities and methods to improve IBC outcomes.
1. Background
Inflammatory breast cancer (IBC) is a relatively rare, yet
aggressive, subtype of locally advanced breast cancer, with
median overall survival less than 4 years [1, 2]. IBC incidence
ranges from 1 to 6% of all breast cancers (most recent
data suggests 2.5%) among women in the United States,
yet they account for 7% of all breast cancer deaths [3–9].
Approximately 25% of IBC patients present with distant
disease at diagnosis [4]. IBC was historically a uniformly
fatal disease, but the implementation of multifactorial treat-
ments with neoadjuvant chemotherapy, surgery, and radia-
tion has improved survival over the past two decades [10–13].
Response to chemotherapy is one of the strongest predictors
of survival [14]. Nevertheless, many patients experience
disease recurrence, most frequently to bone, brain, lung, or
liver [15].
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With regard to patient characteristics, IBC patients tend
to be younger than other breast cancer patients, with a
median age at diagnosis of 57 years for IBC compared to 61.9
for all breast cancers combined [5, 6]. IBC has been shown to
have a higher incidence rate among black women than white
women (3.1 per 100,000 women-years for blacks compared to
2.2 for whites) [3]. Further, overall survival has been reported
to be significantly worse for blacks than whites [6]. High BMI
is associated with an increased risk for IBC compared to non-
IBC breast cancer [16, 17].
Survival tends to be poorer in IBC patients compared
to non-IBC breast cancer patients regardless of histologic
subtype [18, 19]. Data from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER) Pro-
gram indicate that the 5-year survival rate was 34% for
IBC patients from 1988 to 2001 compared to about 87%
for other invasive breast cancers [20]. Although survival for
cases of IBC has improved with multimodal therapy [21],
recent population statistics still demonstrate much lower
median survival for IBC cases (2.9 years) than for cases of
locally advanced breast cancer (6.4 years) and nonmetastatic
breast cancer (>10 years). Therefore, there is great need to
identify factors impacting survival in IBC, and the objective
of this study was to identify those factors. Using a multistate,
population-based sample of patients with IBC, we examined
the demographics of these IBC patients compared to patients
with locally advanced breast cancer (LABC) because IBCwas
earlier thought to be a more aggressive form of LABC [10],
and LABC has been used frequently as a comparison group
for IBC [22]. Further, we examined differences in IBC patient
survival based on patient characteristics.
2. Materials and Methods
2.1. Patient Population and Data Sources. The Breast and
Prostate Cancer Data Quality and Patterns of Care Study
(POC-BP) is the third and most comprehensive POC study
from the National Program of Cancer Registries of the Cen-
ters for Disease Control and Prevention (CDC). It collected
information on breast and prostate cancer patients diagnosed
in 2004 in seven states (California, Georgia, Kentucky,
Louisiana,Minnesota, North Carolina, andWisconsin). Can-
cer registry data were supplemented by reabstracting hospital
records and obtaining information about adjuvant treatment
and comorbidity from physicians and outpatient facilities
and linkages with secondary files such as census data or
hospital/physician files. The combined sample size was 9,142
breast cancer patients, fromwhich we extracted patients with
IBC (𝑛 = 170) and compared them to patients with LABC
(𝑛 = 375). Our IBC population was defined as T4d, N0-2,
and M0-1. LABC was defined as a diagnosis of stage IIIB or
IIIC (this does not include stage III not otherwise specified).
As another comparison group, “all else,” we included all 9,142
breast cancer patients minus in situ cases and those classified
as IBC or LABC (𝑛 = 7,079).
2.2. Covariates of Interest. Patient race and ethnicity were
attained from medical records and categorized into the
following groups: non-Hispanic white, non-Hispanic black,
Hispanic, and others. Insurance status at diagnosis was
categorized into the following five groups: private, Medi-
care/other public, Medicaid, none, and unknown.The private
insurance group also included cases where the patient had
both Medicare and private insurance. “Other public insur-
ance” consisted of patients with TRICARE, other military
insurance, Veterans Affairs, or Indian Health Service cover-
age. The Medicaid group also included women on Medicare
with Medicaid eligibility and other government programs.
Body mass index (BMI) at the time of diagnosis was cate-
gorized into three groups: <25 kg/m2 (normal), 25–29 kg/m2
(overweight), and ≥30 kg/m2 (obese). Area measures were
constructed from 2000 US census data linked to the census
tract of the patient’s residence at the time of diagnosis.
Hospital/institution characteristics were based on the
facility in which the patient received breast cancer surgery
regardless of the location of other treatments because most
referrals for adjuvant therapy are made by a surgeon [23].
If the patient did not receive surgery, then we used the
institution where the patient received chemotherapy. If the
patient did not receive chemotherapy, then we used the
institution where the patient received endocrine therapy.
Patient comorbidities were assessed using the Adult
Comorbidity Evaluation-27 (ACE-27) developed by Piccirillo
et al. [24]. The ACE-27 was chosen because it reflects a wide
range of coexisting conditions and disease severity relevant to
cancer therapy choice and outcome.
2.3. Statistical Analysis. Chi-square tests were used to com-
pare IBC to LABC and all other breast cancer patients.
Kaplan-Meier survival curves were drawn to compare
patients according to different characteristics, with follow-
up beginning at the date of diagnosis through either death
or censoring, whichever occurred first. Log-rank tests were
calculated to compare survival curves. Cox proportional
hazards modeling was used to assess the predictive value
of certain factors on the survival of IBC patients. All sig-
nificance tests were two-sided, and 𝑃 values less than 0.05
were considered statistically significant. All statistics were
weighted by the sampling fractions used by each state registry
for the respective sampling stratum to represent the source
population. SAS procedures for survey data were used.
3. Results
3.1. Demographic and Clinical Characteristics of IBC Patients
versus LABC Patients. We assessed differences in demo-
graphics of the patients as well as molecular and clinical
characteristics of the disease in IBC compared to LABC
and all other breast cancers (Table 1). The mean age of
IBC patients was 57.7 years compared to 58.9 for LABC
and 59.5 for all others. IBC patients were more likely to be
of black race than other breast cancer patients. A greater
percentage of IBC patients were obese (BMI > 30) compared
to other breast cancer patients. IBC patients were more
likely to have comorbidities than other breast cancer patients,
and the severity of those comorbidities was also greater for
IBC patients compared to other breast cancer patients; no
differences in comorbidity number or severity were observed
Journal of Cancer Epidemiology 3
Table 1: Demographic characteristics of patients with inflammatory breast cancer comparedwith locally-advanced and all other breast cancer
patients, Patterns of Care Study, 2004–2012.
Characteristic IBC LABC (IIIB, C) IBC versus LABC
𝑃 value∗∗
Others IBC versus others
𝑃 value∗∗Number %∗ Number %∗ Number %∗
Total 170 375 7079
Age at diagnosis, years
<50 50 26.4 113 32.2
0.02
2024 26.0
0.0950–59 49 34.1 91 21.3 1818 25.9
60–69 36 22.6 76 18.8 1448 21.1
≥70 35 16.9 95 27.6 1789 27.0
Ancestry/ethnicity
European, non-Hispanic 81 68.4 174 66.4
0.54
4083 76.4
0.002African, non-Hispanic 68 22.4 138 21.6 1925 13.7
Hispanic 14 7.6 38 8.2 615 6.2
Other 7 1.6 25 3.9 456 3.8
Body mass index (kg/m2)
<25 28 16.2 88 25.5
0.28
1743 27.0
0.0525–29 35 24.4 77 22.1 1626 23.5
≥30 66 34.9 133 34.1 2086 27.6
Unknown 41 24.4 77 18.4 1624 21.9
Number of comorbidities
0 58 34.8 154 42.8
0.08
3162 45.3
0.031 57 34.3 105 27.5 2028 28.7
2 35 23.2 61 16.5 1127 15.2
≥3 20 7.7 55 13.2 762 10.8
Piccirillo Comorbidity Score
None 55 33.0 146 41.0
0.53
2948 42.1
0.01
Mild 68 40.6 147 37.5 2957 41.5
Moderate 29 17.0 49 14.1 709 10.0
Severe 16 7.9 27 6.0 287 3.8
Unknown 2 1.6 6 1.4 178 2.6
Method of detection
Screening mammography 8 3.8 72 19.9
<0.0001
3035 44.0
<0.0001
Clinical or self-breast exam 22 9.1 60 16.4 1055 13.7
Self-detection of lump 58 43.3 163 44.2 2119 29.9
Self-detection, no lump 74 37.1 62 14.6 399 5.2
Other, unknown 8 6.7 18 4.9 471 7.1
Patient health insurance
Private 77 48.4 167 52.3
0.58
4077 60.5
0.0004Medicare only/public 38 21.3 88 24.5 1553 23.0
Medicaid 39 20.5 84 15.4 999 10.3
No insurance or unknown 16 9.9 36 7.8 450 6.2
∗Percentages weighted based on sampling design. ∗∗𝑃 values from chi-square tests.
between IBC and LABC patients. IBC patients were more
likely to be diagnosed by signs or symptoms other than a
lump compared to LABC and all other breast cancer patients.
In addition, IBC patients were more likely to be from areas
with higher poverty compared to other breast cancer patients,
but there was no significant difference compared to LABC
patients (Table 2). IBC patients were more likely to be treated
at large (>400 beds), Commission on Cancer-accredited,
teaching hospitals compared to LABC and all other patients.
3.2. Clinical Metastatic versus Nonmetastatic IBC Patient
Characteristics. We assessed differences in patient character-
istics in IBC patients that presented with clinical metastatic
disease (𝑛 = 63; 37%) versus nonmetastatic disease (𝑛 =
4 Journal of Cancer Epidemiology
Table 2: Contextual characteristics of patients with inflammatory breast cancer compared with locally advanced and all other breast cancer
patients, Patterns of Care Study, 2004–2012.
Characteristic IBC LABC (IIIB, C) IBC versus LABC
𝑃 value∗∗
All else IBC versus all else
𝑃 value∗∗Number %∗ Number %∗ Number %∗
Total 170 375 7079
Poverty (census tract)
<20% below poverty 108 73.8 257 78.1 0.33 5280 82.3 0.01
≥20% below poverty 60 25.6 117 21.4 1779 17.4
Education (census tract)
<25% no high school degree 83 60.2 200 63.1 0.61 4297 68.5 0.07
≥25% no high school degree 85 39.2 174 36.3 2762 31.2
Urbanicity
Urban 94 53.8 185 47.8
0.14
3585 51.3
0.43Rural 23 9.2 63 17.0 1014 13.4
Urban/rural mix 51 36.5 126 34.7 2461 35.0
Unknown 2 0.5 1 0.5 19 0.3
Hospital teaching status
Teaching 73 45.8 136 37.0
0.06
2807 39.2
0.10Other 66 38.2 202 52.1 3330 47.5
Unknown 31 15.9 37 10.9 942 13.3
Hospital size (number of beds)
<200 32 15.1 96 23.3
0.05
1671 21.2
0.17
200–299 20 12.4 77 23.0 1234 18.1
300–399 21 14.7 38 11.4 842 13.2
≥400 66 41.8 127 31.4 2390 34.1
Unknown 31 15.9 37 10.9 942 13.3
Hospital Commission on Cancer Accreditation
No 59 29.3 152 40.0
0.06
2654 38.1
0.05Yes 87 57.8 191 50.1 3558 49.1
Unknown 24 12.9 32 9.9 867 12.7
∗Percentages weighted based on sampling design. ∗∗𝑃 values from chi-square tests.
107; see Supplemental Table 1 in the Supplementary Mate-
rial available online at https://doi.org/10.1155/2017/7574946).
There were no differences in age betweenmetastatic and non-
metastatic IBC patients. Patients presenting with metastatic
disease were more likely to be of black race, be insured by
Medicaid, and be from areas of higher poverty and more
urban areas.
3.3. Factors Predicting Survival of IBC Patients. We com-
pared all-cause and breast cancer-related survival of IBC
patients to LABC and all other breast cancer patients. IBC
and LABC patients both had significantly worse survival
compared to all other breast cancer patients, and IBC
patients had significantly worse survival compared to LABC
patients (both all-cause and breast cancer-related survival;
Supplemental Figure 1). IBC patients of black race and
Hispanic ethnicity had worse all-cause and breast cancer-
related survival compared to white IBC patients (Figure 1).
We also compared survival based on ER/PR status, finding
that IBC patients with ER/PR-positive tumors had better
all-cause and breast cancer-specific survival (Supplemental
Figure 2). Lastly, IBC patients who presented with metastatic
disease had significantly worse all-cause and breast cancer-
related survival compared to nonmetastatic (Supplemental
Figure 3).
Differences in IBC patient survival were also analyzed
based on patient characteristics using Cox proportional
hazards modeling (Table 3). All Cox models were adjusted
for age and metastasis on presentation and weighted based
on sampling. Black and Hispanic IBC patients had worse
survival compared to white IBC patients; this disparity was
not observed in LABC patients. IBC patients with BMI <
25 had 5-year survival rates of 68.5% compared to 41.6%
for overweight (BMI 25–29) patients and 64.7% for obese
patients (BMI ≥ 30); there were no differences in survival
rates of LABC patients based on BMI. Higher number and
severity of comorbidities correlated with worse survival rates,
both for IBC and for LABC. IBC patients with Medicaid
had worse survival than IBC patients with private insurance
or Medicare; the same trend was observed in LABC. Fur-
thermore, IBC patients from areas of higher poverty and
lower education had worse survival rates, but this was not
Journal of Cancer Epidemiology 5
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Figure 1: All-cause overall survival (a) and breast cancer-related survival (b) among inflammatory breast cancer patients based on race and
ethnicity, Patterns of Care, 2004–2012.
the case for LABC patients. Patients with metastatic disease
on presentation and with ER− and PR− negative tumors
had worse survival. Survival was worse in patients with
poorly differentiated tumors compared to well or moderately
differentiated tumors.
4. Discussion
IBC is a rare yet lethal form of LABC. Epidemiological
research on IBChas been lacking due to a low incidence of the
disease, and most data regarding outcomes of IBC patients
are from small single institution series. This Patterns of Care
Study with patients from 7 states compared IBC to LABC and
all other breast cancers in patient and tumor characteristics
and survival. We found that IBC patients had significantly
worse survival than LABC and other breast cancer patients.
Our data revealed a 5-year survival rate of 44% for IBC
compared to 58% for LABC and 84% for all other cases.
This is consistent with other studies [25–27]. Despite the
advent of multimodal therapy, including both neoadjuvant
and adjuvant chemotherapy, IBC continues to carry a poor
prognosis.
The most striking findings in this dataset are the vari-
ations in risk and severity of IBC cases based on race and
socioeconomic status. A higher percentage of black breast
cancer patients have IBC compared to white breast cancer
patients. Previous studies have demonstrated similar racial
disparities in IBC [3, 4, 28–31]. Furthermore, IBC patients
weremore likely to be from areas of higher poverty compared
to other breast cancer patients. IBC patients presenting with
metastatic disease were more likely to be of black race and
from poorer, more urban areas. With regard to survival, we
found that patients from areas of higher poverty and lower
education had worse survival rates. In addition, black and
Hispanic IBC patients had worse survival compared to white
IBC patients. Consistent with this, white race has been shown
to be an independent predictor of better survival in IBC
[32]. It is important for physicians to be cognizant of these
disparities so that the causes of such disparities can be better
addressed.
The major potential reasons for this disparity in IBC
incidence and outcomes based on race and socioeconomic
status include (1) decreased access to care; (2) differences in
biology due to race or heritage; (3) increasedmedicalmistrust
among minorities [33]; and (4) the erythema associated
with IBC being less visible in patients with darker skin,
potentially leading to a delay in diagnosis [34]. Based on
our data and others [35, 36], we conclude that the first
explanation is most justified; that is, black IBC patients
have worse outcomes because they have reduced access to
care, not because of biological differences based on race or
heritage. Because race/ethnicity and socioeconomic status are
so strongly correlated, black patients are less likely to get
adequate breast cancer screening, and after diagnosis they
generally have more limited access to care, limited treatment
options, and difficulty with treatment adherence [37]. Also
supporting this claim, Tunisia had a high rate of IBC which
has decreased at least in part due to improved socioeconomic
status [38].
In our dataset, only 3.8% of IBC tumors were found by
screeningmammography.Many patients were diagnosed as a
result of symptoms other than a lump.This is consistent with
previous reports [15]. There are three hypotheses that could
explain this finding. First, it is possible that these women
were not getting regular screening mammograms. Secondly,
it may be due to the aggressive nature of IBC, suggesting that
these tumors developed rapidly between screenings. Lastly,
it may be because mammography itself is less effective at
detecting these tumors. Some reports have suggested that
IBC is difficult to detect using mammography or clinical
6 Journal of Cancer Epidemiology
Table 3: Hazard ratios for inflammatory breast cancer patient mortality based on patient characteristics, Patterns of Care Study, 2004–2012.
Characteristic
At risk Cause of death
Breast cancer Any cause
Number %∗ Number of deaths HR (95% CI)∗∗ Number of deaths HR (95% CI)∗∗
Total 170 91 121
Age at diagnosis, years
<50 50 26.4 25 1 (ref.) 30 1 (ref.)
50–59 49 34.1 31 2.05 (1.03–4.08) 37 1.89 (1.03–3.47)
60–69 36 22.6 18 1.15 (0.48–2.74) 24 1.28 (0.65–2.53)
≥70 35 16.9 17 1.92 (0.81–4.56) 30 2.53 (1.34–4.77)
Ancestry/ethnicity
European, non-Hispanic 81 68.4 36 1 (ref.) 48 1 (ref.)
African, non-Hispanic 68 22.4 43 1.76 (1.05–2.97) 56 1.86 (1.19–2.91)
Hispanic 14 7.6 8 1.14 (0.35–3.71) 11 1.57 (0.72–3.40)
Other 7 1.6 4 1.25 (0.67–2.33) 6 1.66 (0.88–3.13)
Piccirillo Comorbidity Score
None 55 33.0 26 1 (ref.) 35 1 (ref.)
Mild 68 40.6 38 0.55 (0.27–1.12) 48 0.48 (0.27–0.87)
Moderate 29 17.0 14 1.01 (0.43–2.41) 21 0.86 (0.39–1.86)
Severe 16 7.9 13 2.77 (1.35–5.69) 16 2.64 (1.32–5.27)
Unknown 2 1.6 0 — 1 0.88 (0.44–1.75)
Metastasis on presentation
Yes 63 31.1 49 3.20 (1.87–5.48) 59 2.97 (1.86–4.73)
No 107 68.9 42 1 (ref.) 62 1 (ref.)
ER/PR status
ER+ and/or PR+ 87 49.1 38 0.55 (0.29–1.03) 56 0.54 (0.32–0.92)
ER− and PR− 70 42.9 45 1 (ref.) 54 1 (ref.)
Unknown 13 8.1 8 2.11 (0.76–5.83) 11 1.89 (0.71–5.05)
HER2 status
Positive 62 35.9 33 0.74 (0.40–1.36) 42 0.90 (0.55–1.49)
Negative 83 48.2 45 1 (ref.) 61 1 (ref.)
Unknown 25 16.0 13 0.84 (0.19–3.70) 18 0.80 (0.21–3.07)
Grade
Well or moderately differentiated 31 22.4 13 1 (ref.) 21 1 (ref.)
Poorly differentiated 112 66.0 64 1.84 (0.72–4.71) 84 1.83 (0.91–3.69)
Undifferentiated 6 1.8 2 0.46 (0.05–3.91) 2 0.38 (0.05–2.81)
Unknown 21 9.9 12 1.12 (0.39–3.20) 14 0.84 (0.36–1.96)
ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; ref., reference group. ∗Percentagesweighted based on sampling design. ∗∗Cox proportional
hazards models adjusted for age, metastasis on presentation, ER/PR status, treatment, and sampling weights and strata within each study center.
breast exam because there is often no mass [2]. When there
is a mass, it is often masked by diffusely increased breast
density. IBC is found in a disproportionate number of women
of low socioeconomic status, and breast cancer screening
is generally lower in people of lower socioeconomic status
[39].
IBC patients tend to have worse comorbidities than other
breast cancer patients. One study found that women with
endocrine disease, psychiatric disorders, and hematologic
disease were more likely to be diagnosed with advanced
breast cancer, while those with cardiovascular disease, mus-
culoskeletal disorders, gastrointestinal disease, benign breast
disease, and genitourinary disorders were less likely to be
diagnosed with advanced breast cancer after controlling for
number of physician visits [40]. The risk for death among
breast cancer patients depends heavily on the stage of illness
at diagnosis, and comorbid illnesses are thought to increase
the risk of late stage disease for a number of reasons [40,
41]. Some suggest that early symptoms of breast cancer
are sometimes confused with the symptoms of comorbid
illnesses or are less significant than other health problems
[42]. Women with comorbidities are more likely to access
health care and therefore may be more likely to get screened
for breast cancer [43]. However, some studies suggest that
comorbidities can be a barrier to breast cancer screening [44];
our data tends to support this hypothesis. Lastly, there may
be some interaction between certain comorbidities and the
development of cancer; for example, diabetes is thought to
Journal of Cancer Epidemiology 7
increase risk of cancer via hyperinsulinemia, hyperglycemia,
and inflammation [45].
A major strength of this study is its large-scale
population-based design, including data from seven states.
Other strengths were the inclusion of National Program
of Cancer Registries that did not participate in previous
POC studies and comprehensive treatment information.
Limitations include the small number of IBC cases, as all
past IBC research has been hampered by this as well.
5. Conclusion
In conclusion, this study highlights potential reasons for
disparities in IBC incidence and severity, which represent
targetable—albeit not modifiable—factors. We identify dis-
parities in race and socioeconomic status on the risk of IBC
as well as IBC outcomes. Further work is needed to reveal the
causes behind these disparities and methods to improve IBC
outcomes.
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